MX389468B - Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña - Google Patents

Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña

Info

Publication number
MX389468B
MX389468B MX2019006844A MX2019006844A MX389468B MX 389468 B MX389468 B MX 389468B MX 2019006844 A MX2019006844 A MX 2019006844A MX 2019006844 A MX2019006844 A MX 2019006844A MX 389468 B MX389468 B MX 389468B
Authority
MX
Mexico
Prior art keywords
hydroxybutyrates
glyceryl
control
migraine symptoms
migraine
Prior art date
Application number
MX2019006844A
Other languages
English (en)
Spanish (es)
Other versions
MX2019006844A (es
Inventor
Sami Hashim
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of MX2019006844A publication Critical patent/MX2019006844A/es
Publication of MX389468B publication Critical patent/MX389468B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2019006844A 2016-12-23 2017-11-30 Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña MX389468B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/389,828 US20180177753A1 (en) 2016-12-23 2016-12-23 Glyceryl 3-hydroxybutyrates for migraine symptom management
PCT/US2017/063832 WO2018118369A1 (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Publications (2)

Publication Number Publication Date
MX2019006844A MX2019006844A (es) 2019-08-16
MX389468B true MX389468B (es) 2025-03-20

Family

ID=62624821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006844A MX389468B (es) 2016-12-23 2017-11-30 Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña

Country Status (13)

Country Link
US (2) US20180177753A1 (enExample)
EP (1) EP3558458B1 (enExample)
JP (1) JP7108320B2 (enExample)
KR (1) KR102390608B1 (enExample)
CN (1) CN110167637B (enExample)
BR (1) BR112019012431A2 (enExample)
CA (1) CA3046350C (enExample)
ES (1) ES2962879T3 (enExample)
IL (1) IL267540B (enExample)
MX (1) MX389468B (enExample)
MY (1) MY190308A (enExample)
PT (1) PT3558458T (enExample)
WO (1) WO2018118369A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
WO2018115158A1 (en) 2016-12-21 2018-06-28 Universitäts-Kinderspital Beider Basel Migraine prevention and treatment
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
ES2965646T3 (es) * 2019-01-17 2024-04-16 Ketolipix Therapeutics Gmbh Procedimiento para la producción de lípidos que contienen unidades estructurales a base de glicéridos de ácidos hidroxicarboxílicos
WO2020147978A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von glyceriden von hydroxycarbonsäuren
IL278422B (en) * 2019-03-14 2022-09-01 Neuroenergy Ventures Inc A flavor masking formulation for ketone body compounds
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
CN113710243A (zh) * 2019-05-30 2021-11-26 神经活力投资公司 甘油三(β-羟基丁酸酯)与神经元短暂性脑缺血发作
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
AU2022387742A1 (en) * 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
WO2023094654A1 (en) 2021-11-26 2023-06-01 Arxada Ag Acetoacetate based ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
US12622967B2 (en) * 2022-01-18 2026-05-12 Today, Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
EP4605371A1 (en) 2022-10-18 2025-08-27 Arxada AG Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
AU2010207597A1 (en) * 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) * 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
SG11201809211QA (en) 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
JP2019526607A (ja) 2016-09-12 2019-09-19 ユニバーシティ・オブ・サウス・フロリダ ケトンにより改善された神経再生
WO2018115158A1 (en) 2016-12-21 2018-06-28 Universitäts-Kinderspital Beider Basel Migraine prevention and treatment

Also Published As

Publication number Publication date
MX2019006844A (es) 2019-08-16
BR112019012431A2 (pt) 2020-04-14
IL267540A (en) 2019-08-29
US20190117612A1 (en) 2019-04-25
CA3046350A1 (en) 2018-06-28
CN110167637B (zh) 2023-03-14
JP2020502250A (ja) 2020-01-23
PT3558458T (pt) 2023-11-27
US20180177753A1 (en) 2018-06-28
EP3558458A1 (en) 2019-10-30
CA3046350C (en) 2022-08-16
EP3558458B1 (en) 2023-10-18
KR102390608B1 (ko) 2022-04-25
MY190308A (en) 2022-04-13
KR20190099465A (ko) 2019-08-27
CN110167637A (zh) 2019-08-23
JP7108320B2 (ja) 2022-07-28
US10792269B2 (en) 2020-10-06
IL267540B (en) 2022-07-01
WO2018118369A1 (en) 2018-06-28
EP3558458A4 (en) 2020-08-12
ES2962879T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
MX2019006844A (es) Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña.
IL261627B (en) A method and system for optimizing and predicting demand response
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
IL263680A (en) Combination therapies
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
LT3429571T (lt) Sd1 inhibitorių deriniai, skirti neoplastinių ligų gydymui
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
ECSP19077969A (es) Compuesto heterociclico
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
CL2016001095A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
CL2019000505A1 (es) Unidad de tratamiento para tratamiento de hilo en línea.
TW201713333A (en) Methods of treating a neurodegenerative disease
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
MX2018007123A (es) Control remoto para el control de aparatos mediante la desviacion de la señal de realimentacion del control nativo al control remoto y metodos para el mismo.
BR112019020338A8 (pt) Composição para produção de tagatose, e, método de produção de tagatose
MX2020009939A (es) Metodos para tratar el sindrome de prader-willi.
IL276853B2 (en) SGC-driven forms of aggression
MX2018013660A (es) Seleccion de cepas bacterianas utiles en el tratamiento de la alergia.
PL3683648T3 (pl) Sposób sterowania systemem dostaw energii
EP3766155C0 (en) REDUNDANT POWER SUPPLY SYSTEM